[1]阎 雪,路栋栋.罗氟司特联合布地奈德对慢性阻塞性肺疾病急性加重期患者呼吸力学指标及氧化应激反应的影响[J].陕西医学杂志,2022,51(1):73-76.[doi:DOI:10.3969/j.issn.1000-7377.2022.01.019]
　YAN Xue,LU Dongdong.Effects of roflumilast combined with budesonide on respiratory mechanics and oxidative stress in patients with acute exacerbation of chronic obstructive pulmonary disease[J].,2022,51(1):73-76.[doi:DOI:10.3969/j.issn.1000-7377.2022.01.019]
点击复制

罗氟司特联合布地奈德对慢性阻塞性肺疾病急性加重期患者呼吸力学指标及氧化应激反应的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年1期
页码:
73-76
栏目:
药物与临床
出版日期:
2022-01-05

文章信息/Info

Title:
Effects of roflumilast combined with budesonide on respiratory mechanics and oxidative stress in patients with acute exacerbation of chronic obstructive pulmonary disease
作者:
阎 雪; 路栋栋
(锦州医科大学附属第一医院呼吸内科,辽宁 锦州 121000)
Author(s):
YAN Xue; LU Dongdong
(Department of Respiratory Medicine,the First Affiliated Hospital of Jinzhou Medical University,Jinzhou 121000,China)
关键词:
慢性阻塞性肺疾病急性加重期;  罗氟司特;  布地奈德;  呼吸力学;  肺功能;  疗效;  氧化应激
Keywords:
Acute exacerbation of chronic obstructive pulmonary disease;  Roflumilast;  Budesonide;  Respiratory mechanics;  Lung function;  Curative effect;  Oxidative stress
分类号:
R 563
DOI:
DOI:10.3969/j.issn.1000-7377.2022.01.019
文献标志码:
A
摘要:
目的:探究罗氟司特联合布地奈德对慢性阻塞性肺疾病急性加重期(AECOPD)患者呼吸力学指标及氧化应激反应的影响。方法:选择90例AECOPD患者,按随机数表法将患者分为A组与B组,各45例。B组接受布地奈德治疗,A组在B组基础上联合罗氟司特治疗。观察两组疗效,并将肺功能指标[峰值呼气流速(PEF)、第1秒用力呼气量(FEV1)、用力肺活量(FVC)]、呼吸力学指标[气道阻力(Raw)、气道峰压(PIP)、动态顺应性(Cdyn)]及氧化应激指标[谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、丙二醛(MDA)]进行治疗前、后对比。结果:A组治疗总有效率95.56%,高于B组80.00%(P<0.05); 治疗后,两组PEF、FEV1、FVC比治疗前高,且A组高于B组(P<0.05); 治疗后,两组Raw、PIP比治疗前低,Cdyn比治疗前高,且A组优于B组(均P<0.05); 治疗后,两组GSH-Px、SOD比治疗前高,MDA比治疗前低,且A组优于B组(均P<0.05)。结论:对AECOPD患者进行罗氟司特联合布地奈德治疗疗效较好,可以明显改善患者肺功能与呼吸力学,减轻氧化应激反应,促进恢复。
Abstract:
Objective:To explore the effects of roflumilast combined with budesonide on respiratory mechanics indexes and oxidative stress response in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:A total of 90 patients with AECOPD were selected and divided into group A and group B according to the random number table method,with 45 cases in each group.Patients in group B were treated with budesonide,while patients in group A were treated with roflumilast combined with budesonide.Therapeutic effects of the two groups were observed.Lung function indicators [Peak expiratory flow(PEF),Forced expiratory volume in one second(FEV1),and Forced vital capacity(FVC)],respiratory mechanics indexes [Airway resistance(Raw),Peak inspiratory pressure(PIP),Compliance dynamic(Cdyn)] and oxidative stress indexes [Glutathione peroxidase(GSH-Px),Superoxide dismutase(SOD),and Malonaldehyde(MDA)] before and after treatment were compared.Results:The total effective rate of treatment in group A was 95.56%,higher than 80.00% in group B(P<0.05).After treatment,PEF,FEV1 and FVC were increased in the two groups,and these indicators in group A were higher than group B(all P<0.05).After treatment,Raw and PIP were reduced,Cdyn was increased in the two groups,and the three in group A were better than those in group B(all P<0.05).After treatment,GSH-Px and SOD were increased,MDA was reduced in the two groups,and the three in group A were better than those in group B(all P<0.05).Conclusion:Roflumilast combined with budesonide is effective in the treatment of patients with AECOPD,which can significantly improve the patients' lung function and respiratory mechanics,reduce oxidative stress response,and promote recovery.

参考文献/References:

[1] 舒 攀,张 莉,侯云秋,等.逐瘀通脉消栓方预防慢性阻塞性肺疾病急性加重期机械通气患者下肢深静脉血栓临床研究[J].陕西中医,2021,42(9):1204-1207.
[2] Wu CW,Lan CC,Hsieh PC,et al.Role of peripheral eosinophilia in acute exacerbation of chronic obstructive pulmonary disease[J].World J Clin Cases,2020,8(13):2727-2737.
[3] 何文波,陈兆军.布地奈德气雾剂联合正压通气治疗慢性阻塞性肺疾病急性加重期并发严重呼吸衰竭的临床研究[J].中国临床药理学杂志,2019,35(11):1105-1108.
[4] 程 莎,代泽兰,肖 创,等.罗氟司特对亚洲慢性阻塞性肺疾病患者肺功能影响的Meta分析[J].中国药房,2019,30(8):1112-1117.
[5] Aggarwal T,Wadhwa R,Thapliyal N,et al.Oxidative,inflammatory,genetic,and epigenetic biomarkers associated with chronic obstructive pulmonary disorder[J].J Cell Physiol,2019,234(3):2067-2082.
[6] Domnik NJ,James MD,Scheeren RE,et al.Deterioration of nighttime respiratory mechanics in COPD:Impact of bronchodilator therapy[J].Chest,2021,159(1):116-127.
[7] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[8] 付东伟,崔吉宏,涂钰林.沙美特罗替卡松与氨茶碱联合治疗对慢性阻塞性肺病急性加重期疗效和氧化应激的影响[J].中国现代医学杂志,2017,27(2):119-122.
[9] 袁梦鑫,陈雨莎,欧雪梅,等.慢性阻塞性肺疾病急性加重期肺康复研究进展[J].中国呼吸与危重监护杂志,2020,19(1):92-95.
[10] Ishfaq N,Gul N,Zaka N.Outcome of early use of non-invasive positive pressure ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease[J].Pak J Med Sci,2019,35(6):1488-1492.
[11] 姚志强,袁维蔚,黄桂琼.布地奈德对慢性阻塞性肺疾病患者FeNO,hs-CRP和血浆Fbg水平变化的影响[J].河北医药,2019,41(7):1018-1021.
[12] 王秋华,王 丽,李 丹,等.布地奈德联合特布他林治疗慢性阻塞性肺疾病急性加重期的临床疗效分析[J].山西医药杂志,2020,49(19):2643-2645.
[13] 雍文穆,邓淑娇,李 森.异丙托溴胺联合布地奈德福莫特罗粉治疗中度慢性阻塞性肺病疗效及对患者肺功能的影响研究[J].陕西医学杂志,2020,49(3):349-352,356.
[14] 童 琳,汤慧芳.罗氟司特治疗慢性阻塞性肺疾病的临床研究进展[J].世界临床药物,2017,38(4):291-295.
[15] Rhee CK,Kim DK.Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease[J].Korean J Intern Med,2020,35(2):276-283.
[16] 刘志群,王国茗,于 贺.罗氟司特治疗慢性非阻塞性肺疾病急性加重期的疗效观察[J].西南国防医药,2019,29(2):156-158.
[17] Wang K,Liang ZY,Wang XL,et al.Continuous positive airway pressure improves respiratory mechanics and efficiency of neural drive in stable COPD:An exploratory study[J].J Thorac Dis,2020,12(3):626-638.
[18] 姜 辉,李 娟,陈向荣.自动插管补偿联合压力支持通气对慢性阻塞性肺疾病患者呼吸力学的影响[J].华南国防医学杂志,2017,31(10):661-664.
[19] 贾美莹,朱 波,王银叶.乌司他丁对AECOPD合并呼吸衰竭患者呼吸力学和氧化应激的影响[J].海南医学,2018,29(24):3420-3422.
[20] 刘新艳.慢性阻塞性肺疾病急性加重期患者氧化应激与肺功能的相关性研究[J].河北医药,2020,42(16):2490-2492,2496.
[21] 杨欣燐,付松泉,闫亚男,等.丹参多酚酸盐联合布地奈德对慢性阻塞性肺疾病急性加重期氧化应激的影响[J].西部中医药,2019,32(9):79-81.
[22] 李 静,林忠贤,周国红.氨茶碱联合布地奈德福莫特罗对AECOPD患者氧化应激及肺功能的影响[J].海南医学,2020,31(2):167-170.

相似文献/References:

[1]马 南,周冰洁,张建银.血清Toll样受体4、氨基末端脑钠肽前体、甲壳质酶蛋白40水平与慢性阻塞性肺疾病患者急性加重期治疗预后的相关性[J].陕西医学杂志,2025,54(4):502.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.013]
　MA Nan,ZHOU Bingjie,ZHANG Jianyin.Correlation between serum TLR4,NT-proBNP,YKL-40 levels and prognosis of patients with acute COPD exacerbation[J].,2025,54(1):502.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.013]

备注/Memo

备注/Memo:
基金项目:辽宁省教育厅科学技术研究项目(JYTJCZR2020057)
更新日期/Last Update: 2022-01-09